mRNA Synthesis Reagents Product Catalogue

We present a whitepaper on one-stop high-performance reagents and customized services covering the full workflow of mRNA in vitro transcription, modification and production.

Key Insights:

  • Industry Challenges: The mRNA manufacturing process faces multiple pain points, including unstable transcription yield, incomplete capping and poly(A) tailing, residual DNA/impurities, RNA degradation, and a lack of integrated high-quality raw materials and supporting enzymes for full-process production.
  • Proposed Solution: Provide a comprehensive portfolio of mRNA synthesis reagents including restriction enzymes, RNA polymerases, functional enzymes, NTPs, diverse cap analogs and supporting kits, alongside cGMP-compliant custom mRNA synthesis and CDMO services to cover the entire mRNA production chain.
  • Key Benefits:
    • Full-process product layout covering template linearization, IVT, capping, poly(A) tailing and impurity removal
    • High enzymatic activity, high capping efficiency and low impurities, ensuring high integrity and quality of finished mRNA
    • Diversified products compatible with conventional and modified mRNA, supporting RUO and clinical-grade production demands
  • Choosing mRNA Synthesis Reagents & Suppliers: Key criteria include complete product lineup, reagent purity and stability, compatibility with mainstream IVT systems, strict quality control standards, and mature customized production and CDMO capabilities.
  • Hongene's Role: As a professional supplier of nucleic acid raw materials and mRNA synthesis reagents, Hongene offers standardized enzymes, NTPs, cap analogs and ready-to-use kits, and delivers customized mRNA production services. It supports customers from early-stage research to clinical development for mRNA vaccines, drugs and related research projects.

(To explore detailed product specifications, reaction protocols, ordering information and customized service solutions, download the complete whitepaper.)


Flyers
Chemoenzymatic ligation FAQ
Brochures
HiXCap™: Rational 5′ Cap Design Enabling Clinical Advancement of Next-Generation mRNA Therapeutics